These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

661 related items for PubMed ID: 20025693

  • 1. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K, Sundström J, Neovius K, Rössner S, Neovius M.
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [Abstract] [Full Text] [Related]

  • 2. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R.
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [Abstract] [Full Text] [Related]

  • 4. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM, Huang BY, Fanchiang JK, Chen CH.
    Chang Gung Med J; 2007 Apr; 30(6):538-46. PubMed ID: 18350737
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [Abstract] [Full Text] [Related]

  • 7. Long-term effects of weight-reducing drugs in hypertensive patients.
    Siebenhofer A, Horvath K, Jeitler K, Berghold A, Stich AK, Matyas E, Pignitter N, Siering U.
    Cochrane Database Syst Rev; 2009 Jul 08; (3):CD007654. PubMed ID: 19588440
    [Abstract] [Full Text] [Related]

  • 8. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan 08; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

  • 9. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials.
    Kim SH, Lee YM, Jee SH, Nam CM.
    Obes Res; 2003 Sep 08; 11(9):1116-23. PubMed ID: 12972682
    [Abstract] [Full Text] [Related]

  • 10. Long-term pharmacotherapy for obesity and overweight.
    Padwal R, Li SK, Lau DC.
    Cochrane Database Syst Rev; 2003 Sep 08; (4):CD004094. PubMed ID: 14584004
    [Abstract] [Full Text] [Related]

  • 11. Orlistat and sibutramine beyond weight loss.
    Mannucci E, Dicembrini I, Rotella F, Rotella CM.
    Nutr Metab Cardiovasc Dis; 2008 Jun 08; 18(5):342-8. PubMed ID: 17928208
    [Abstract] [Full Text] [Related]

  • 12. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A, Jeitler K, Horvath K, Berghold A, Posch N, Meschik J, Semlitsch T.
    Cochrane Database Syst Rev; 2016 Mar 02; 3():CD007654. PubMed ID: 26934640
    [Abstract] [Full Text] [Related]

  • 13. Long-term effects of weight-reducing drugs in hypertensive patients.
    Siebenhofer A, Jeitler K, Horvath K, Berghold A, Siering U, Semlitsch T.
    Cochrane Database Syst Rev; 2013 Mar 28; (3):CD007654. PubMed ID: 23543553
    [Abstract] [Full Text] [Related]

  • 14. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
    Johansson K, Neovius K, DeSantis SM, Rössner S, Neovius M.
    Obes Rev; 2009 Sep 28; 10(5):564-75. PubMed ID: 19460116
    [Abstract] [Full Text] [Related]

  • 15. Long-term pharmacotherapy for obesity and overweight.
    Padwal R, Li SK, Lau DC.
    Cochrane Database Syst Rev; 2004 Sep 28; 2003(3):CD004094. PubMed ID: 15266516
    [Abstract] [Full Text] [Related]

  • 16. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
    Scheen AJ, Ernest P.
    Diabetes Metab; 2002 Dec 28; 28(6 Pt 1):437-45. PubMed ID: 12522323
    [Abstract] [Full Text] [Related]

  • 17. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep 28; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

  • 18. Long-term persistence with orlistat and sibutramine in a population-based cohort.
    Padwal R, Kezouh A, Levine M, Etminan M.
    Int J Obes (Lond); 2007 Oct 28; 31(10):1567-70. PubMed ID: 17420781
    [Abstract] [Full Text] [Related]

  • 19. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP, SCOUT Investigators.
    Diabetes Obes Metab; 2009 Mar 28; 11(3):239-50. PubMed ID: 18671798
    [Abstract] [Full Text] [Related]

  • 20. Pharmacotherapeutic options for overweight adolescents.
    Dunican KC, Desilets AR, Montalbano JK.
    Ann Pharmacother; 2007 Sep 28; 41(9):1445-55. PubMed ID: 17652127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.